Loading organizations...
Loading organizations...
Develops next-generation antibody therapy for ATTR amyloidosis.
Immutrin has raised $87.0M across 1 funding round.
Immutrin has raised $87.0M in total across 1 funding round.
Immutrin has raised $87.0M in total across 1 funding round.
Immutrin's investors include Frazier Life Sciences, James Topper, Cambridge Enterprise, Mihriban Tuna, Nihal Sinha, Alexander Sinclair Wilson, SR One.
Immutrin has raised $87.0M across 1 funding round. Most recently, it raised $87.0M Immutrin Series A in March 2026.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2026 | $87.0M Immutrin Series A | Frazier Life Sciences, James Topper, James Topper | Cambridge Enterprise, Mihriban Tuna, Nihal Sinha, Alexander Sinclair Wilson, SR One |